Empowering the Medicinal Applications of Bisphosphonates by Unveiling their Synthesis Details.

P-reactants bisphosphonates pharmaceutical applications reactional solvents research-driven studies synthesis improvement

Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
18 Jun 2020
Historique:
received: 21 05 2020
revised: 15 06 2020
accepted: 16 06 2020
entrez: 24 6 2020
pubmed: 24 6 2020
medline: 20 2 2021
Statut: epublish

Résumé

Bisphosphonates (BPs), well-known medicinal compounds used for osteoporosis management, are currently the target of intensive research, from basic pre-formulation studies to more advanced stages of clinical practice. The high demand by the pharmaceutical industry inherently requires an easy, efficient and quick preparation of BPs. Current synthetic procedures are, however, still far from ideal. This work presents a comprehensive compilation of reports on the synthesis of the commercially available bisphosphonates that are pharmaceutical active ingredients. Current limitations to the conventional synthesis are assessed, and paths towards their improvement are described, either through the use of alternative solvents and/or by selecting appropriate ratios of the reactants. Innovative processes, such as microwave-assisted synthesis, are presented as more environmental-friendly and effective methods. The main advantages and setbacks of all syntheses are provided as a way to clarify and promote the development of simpler and improved procedures. Only in this way one will be able to efficiently respond to the future high demand of BPs, mostly due to the increase in life span in occidental countries.

Identifiants

pubmed: 32570958
pii: molecules25122821
doi: 10.3390/molecules25122821
pmc: PMC7356784
pii:
doi:

Substances chimiques

Diphosphonates 0
Solvents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Fundação para a Ciência e a Tecnologia
ID : UIDB/50011/2020 & UIDP/50011/2020
Organisme : Fundação para a Ciência e a Tecnologia
ID : FCT UID/QUI/00062/2019
Organisme : Fundação para a Ciência e a Tecnologia
ID : PD/BD/135104/2017

Références

Drug Deliv. 2005 Jul-Aug;12(4):217-22
pubmed: 16044536
J Environ Sci Health A Tox Hazard Subst Environ Eng. 2007 Sep;42(11):1595-605
pubmed: 17849301
Drug Discov Today. 2008 Aug;13(15-16):677-84
pubmed: 18675762
Drug Discov Today. 2001 Apr 1;6(8):406-416
pubmed: 11301285
Bone. 2011 Jul;49(1):20-33
pubmed: 21497677
Arch Osteoporos. 2013;8:136
pubmed: 24113837
Clin Biochem Rev. 2005 Nov;26(4):97-122
pubmed: 16648882
Bone. 2011 Apr 1;48(4):677-92
pubmed: 21145999
Am J Physiol. 1961 Jun;200:1296-300
pubmed: 13700202
J Am Chem Soc. 2005 Nov 30;127(47):16477-85
pubmed: 16305234
Science. 1969 Sep 19;165(3899):1262-4
pubmed: 5803538
Molecules. 2016 Nov 04;21(11):
pubmed: 27827924
N Engl J Med. 1995 Feb 2;332(5):305-11
pubmed: 7816067
Molecules. 2016 Aug 11;21(8):
pubmed: 27529200
Nat Rev Drug Discov. 2006 Jan;5(1):51-63
pubmed: 16374514
Ann Clin Biochem. 2001 Nov;38(Pt 6):608-23
pubmed: 11732644
Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):834
pubmed: 20069291
South Med J. 2000 Jan;93(1):2-18
pubmed: 10653058
Bone. 2011 Jul;49(1):34-41
pubmed: 21111853
Chem Commun (Camb). 2013 Jul 21;49(57):6400-2
pubmed: 23752868
Science. 2000 Sep 1;289(5484):1504-8
pubmed: 10968780
J Control Release. 2001 Jan 29;70(1-2):183-91
pubmed: 11166418
Eur J Clin Invest. 1970 Mar;1(1):12-8
pubmed: 4319371
Bone. 1995 Nov;17(5 Suppl):505S-511S
pubmed: 8573428
Best Pract Res Clin Endocrinol Metab. 2008 Oct;22(5):671-85
pubmed: 19028351
J Med Chem. 2008 Feb 14;51(3):677-83
pubmed: 18181563
J Am Chem Soc. 2006 Oct 18;128(41):13358-9
pubmed: 17031939
J Med Econ. 2013;16(5):691-700
pubmed: 23441975
J Clin Oncol. 2000 Mar;18(6):1378-91
pubmed: 10715310
Bone. 2011 Jul;49(1):2-19
pubmed: 21555003
J Clin Oncol. 2002 Sep 1;20(17):3719-36
pubmed: 12202673
J Am Chem Soc. 2008 Dec 31;130(52):17648-9
pubmed: 19055348
J Med Chem. 2002 Aug 15;45(17):3721-38
pubmed: 12166945
Bone. 1999 Jul;25(1):97-106
pubmed: 10423031
Pharmazie. 2011 Oct;66(10):804-7
pubmed: 22026164
Mini Rev Med Chem. 2012 Apr;12(4):313-25
pubmed: 22303942
Rheum Dis Clin North Am. 2001 Feb;27(1):197-214
pubmed: 11285996

Auteurs

Jéssica S Barbosa (JS)

CICECO-Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal.
LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal.

Susana Santos Braga (SS)

LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal.

Filipe A Almeida Paz (FA)

CICECO-Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH